- Argus Research initiated coverage on 10x Genomics (NASDAQ: TXG) with a “Buy” rating and a price target of $110.00, suggesting a potential 28.34% upside from its trading price of $85.71.
- The stock demonstrates positive momentum, trading above its 50-day moving average of $60.74 and 200-day moving average of $38.93.
- Despite positive analyst sentiment and market momentum, GuruFocus indicates the stock may be overvalued, with an estimated intrinsic value of $18.34, significantly lower than its recent price of $79.10.
- Recent insider activity shows substantial selling, with Director Shehnaaz Suliman selling 5,723 shares for $464,700.00 and CEO Serge Saxonov selling 25,000 shares for $2.03 million, contributing to a total of $14.40 million in insider sales over the past year with no reported buying.
10x Genomics (NASDAQ: TXG) is a life sciences technology company. It designs and manufactures systems used for biological research, helping scientists analyze cells and their functions. With a market capitalization of approximately $10.88 billion, the company is a significant player in the field of genomics and single-cell analysis.
On September 28, 2026, Argus Research began its coverage of TXG, issuing a “Buy” rating. The firm set a price target of $110.00 for the stock. A price target is an analyst’s estimate of a stock’s future value. At the time, the stock was trading at $85.71, indicating a potential increase of 28.34%.
This positive outlook follows a period of strong stock performance. The current price is well above its 50-day moving average of $60.74 and its 200-day moving average of $38.93. Moving averages show the average price over a period and help identify trends; a price above them often suggests positive momentum.
However, other data points suggest the stock may be overvalued. As highlighted by GuruFocus, the stock’s estimated intrinsic value is $18.34, which is 331.3% lower than its recent price of $79.10. The company also holds a GF Score of 56 out of 100, indicating average overall performance potential.
Recent activity from company insiders also warrants attention. As highlighted by Defense World, Director Shehnaaz Suliman sold 5,723 shares for about $464,700.00. CEO Serge Saxonov also sold 25,000 shares for approximately $2.03 million. Over the past year, insiders have sold $14.40 million in shares with no reported buying.
